USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ETUBICS CORPORATION
Address:
9715 FREMONT AVE N
SEATTLE, WA 98103-3140
Phone:
N/A
URL:
N/A
EIN:
120003520
DUNS:
154453018
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,221,335.00 5
SBIR Phase II $7,323,103.00 3

Award List:

Improved HIV-Adenoviral Vector Vaccine for Re-immunization

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$621,380.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop an adenoviral vector vaccine against HIV that is effective in stimulating cell-mediated immunity in animals previously immune to adenovirus The HIV vaccine will be used to protect against infection and to treat the… More

Development of a Novel CEA Expressing Adenovirus for Treatment

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$112,995.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immunity in animals previously immune to adenovirus. The Ad-CEA vaccine en dpoint is to treat patients with CEA… More

Development of a Novel Her2/neu Expressing Adenovirus for Treatment

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$123,567.00
Agency:
HHS
Principal Investigator:
Frank R. Jones
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral serotype 5 (Ad5) vector vaccine against Ad5[E1-, E2b]-Her2/neu that is effective in stimulating cell-mediated immunity (CMI) in animals previously i mmune to Ad5. The Ad5[E1-, E2b-]- Her2/neu… More

Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$3,353,817.00
Agency:
HHS
Principal Investigator:
Frank R. Jones
Abstract:
DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permi t the delivery of genes, which express… More

Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,470,285.00
Agency:
HHS
Principal Investigator:
Frank R. Jones
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses in subjects previously immune to Adenovirus. The Ad-CEA v accine endpoint is to treat patients with… More

Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$163,405.00
Agency:
HHS
Principal Investigator:
Frank R. Jones – 206-838-5110
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop a therapeutic strategy for H V-associated malignancy based on the role of HPV in the pathogenesis. HPV related cancers express the E6/E7 oncoproteins of HPV that are ideal targets for immune inducing vaccines. We will… More

TAS::75 0849::TAS TOPIC 255 CGMP MANUFACTURE OF A NOVEL HER2/NEU EXPRESSING ADENOVIRUS FOR TREATMENT

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$199,988.00
Agency:
HHS
Principal Investigator:
Joseph Balint – 206-838-5110
Abstract:
This Phase I, SBIR contract is for the development of a new vaccine targeting HER2/neu expressing breast cancers. The vaccine induces both cell-mediated and humoral immunity and the company is planning a first-in-man Phase I/Phase II clinical trial. It isanticipated that this new biotherapeutic… More

TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING AD5 VIRUS

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,499,001.00
Agency:
HHS
Principal Investigator:
Frank Jones – 206-838-5110
Abstract:
Etubics Corporation is clinically testing a new vaccine targeting carcinoembryonic antigen (CEA) expressing cancers in a Phase I/II clinical trials under FDA IND14325. Many cancers express CEA, including colon, breast and pancreatic cancers. It is anticipated that this new biotherapeutic product… More